Focusing on high-density lipoprotein for coronary heart disease risk reduction.
A low level of high-density lipoprotein (HDL) is an acknowledged risk factor for coronary heart disease (CHD). HDL cholesterol (HDL-C) exerts its primary cardioprotective effect through a reverse cholesterol transport process, and suppression of this process has been the focus of the development of novel therapeutic agents for increasing HDL-C levels. Several strategies can be used to increase HDL-C levels to target cardiovascular risk reduction. This article presents a review of the biologic actions of HDL that can serve as a potential basis for antiatherosclerotic activity and discusses strategies for targeting HDL for CHD risk reduction.
Department of Medicine, Section of Cardiology, Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA. michaeldavidson@radiantresearch.com
Michael H
MH
Davidson
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008075:Lipoproteins, HDL / Q000097:blood* / Q000187:drug effects; D011379:Prognosis; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D000924:Anticholesteremic Agents; D008075:Lipoproteins, HDL